The results may be compelling enough to get insurance companies to provide coverage, said Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans.have had trouble getting insurance to cover the weekly injections, which cost more than $1,300 a month, due to the perception that it’s a lifestyle medication.
The individuals had overweight or obesity, as well as existing cardiovascular disease, but no previous history of diabetes. , a Type 2 diabetes medication that has been prescribed off-label for weight loss. Wegovy and Ozempic contain the same active ingredient, semaglutide.Centers for Disease Control and Prevention
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Source: nypost - 🏆 91. / 67 Read more »
Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesityA recent study has found that the weight-loss drug Wegovy can significantly reduce the risk of heart attacks in individuals with obesity. This discovery could lead to an increased demand for the drug and strengthen the argument for insurance coverage. Experts emphasize that obesity should be treated as a serious illness due to its association with various health issues, including heart disease. However, private insurers have been hesitant to cover Wegovy, and Medicare is currently prohibited from covering weight-loss medications.
Source: washingtonpost - 🏆 95. / 72 Read more »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Source: YahooNews - 🏆 380. / 59 Read more »
Popular weight loss drug Wegovy also found to lower the risk of heart attacks, strokesAccording to preliminary results of a new study released by the drug manufacturer, the obesity drug Wegovy reduced the risk of major cardiovascular events by 20% in a clinical trial involving over 17,000 adults aged 45 and older with a history of cardiovascular disease and overweight or obesity.
Source: ABC - 🏆 471. / 51 Read more »